Evaluating the Safety and Immunogenicity of MTBVAC

Recruiting now · Phase 2

Conditions studied: HIV I Infection, Tuberculosis

In brief

The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa

Key facts

Study ID

NCT05947890

Run by

HIV Vaccine Trials Network

People needed

276

Starts

2024-01-30

Expected to finish

2027-04-05

Last updated by the study team

2026-03-12

Who can join

Age: 12 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age of 12 through 55 years, on the day of enrollment.
• Access to a participating HVTN or ACTG CRS and willingness to be followed for the planned duration of the study.
• For volunteers 18 years of age or older: ability and willingness to provide informed consent.
• For volunteers less than 18 years of age: parent or legal guardian is willing and able to provide informed consent for potential participant's study participation; in addition, when applicable per ethics committee policies and procedures, potential participant is willing and able to provide written assent for study participation.
• Assessment of Understanding (AoU): volunteer demonstrates understanding of this study and completes a questionnaire prior to vaccination with verbal demonstration of understanding of all questionnaire items answered incorrectly.
• Prior receipt of BCG vaccine in infancy as determined by the site investigator.
• Agrees not to enroll in another study of an investigational study product until after the last scheduled clinic visit. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 605/A5421 PSRT are required prior to enrollment into HVTN 605/A5421.
• Good general health as shown by medical history, physical exam, and screening laboratory tests and assessed by the site investigator.
• Willingness to receive HIV-related test results.
• For volunteers living without HIV:
• Negative HIV-1 and -2 blood test: Non-US sites may use locally available assays that have been approved by HVTN Laboratory Operations
• Assessed by the clinic staff as having a low likelihood of acquiring HIV and is committed to maintaining behavior that is consistent with a lower likelihood of acquiring HIV through the last required protocol clinic visit
• Willingness to discuss their potential for HIV acquisition and is amenable to HIV risk reduction counseling
• For volunteers living with HIV:
• For both Cohorts 2 and 3: Completed one course of tuberculosis preventive treatment (TPT) as determined by the site investigator.
• Documented HIV viral suppression (Plasma HIV levels < 50 copies/mL) collected at least three months and up to 15 months prior to enrollment (with no intervening HIV-1 RNA results ≥ 50 copies/mL) and from screening labs.
• Has been receiving at least 6 months of ART prior to enrollment, as determined by the site investigator
• For Cohort 2: WHO HIV clinical stage 1 or 2 prior to initiation (or re-initiation in case of treatment interruption/default) of ART.
• CD4+ T-cell count of ≥ 200 cells/mm3 (during screening) 3. For Cohort 3: Advanced HIV disease (defined as CD4 count less than 200 cells/mm3 or WHO HIV clinical stage 3 or 4) prior to initiation (or re-initiation) of ART. Advanced HIV defined as CD4 count less than 200 cells/mm3 or WHO stage 3 or 4. Current CD4+ T-cell count of ≥ 100 cells/ mm3 (during screening)
• Laboratory Inclusion Values - Has normal or Grade 1 results of all of the following at screening:
• Hemoglobin (≥ 9.5 g/dL or ≥ 5.88 mmol/L for males and females less than 13 years of age; ≥ 9.5 g/dL or ≥ 5.88 mmol/L for females 13 years of age and older; ≥ 10.0 g/dL or ≥ 6.19 mmol/L for males 13 years of age and older); White blood cell count (≥ 2000 cells/mm3 or ≥ 2.000 × 109 cells/L); Platelet count (≥ 100,000 cells/mm3 or ≥ 100.000 × 109 cells/L); Creatinine (≤ 1.3 × upper limit of normal [ULN]); Alanine aminotransferase (ALT) (< 2.5 × ULN); Aspartate aminotransferase (AST) (< 2.5 × ULN)
• Negative Hepatitis B surface antigen (HBsAg).
• Negative anti-Hepatitis C virus Abs (anti-HCV), or negative HCV nucleic acid test if the anti-HCV is positive
• For volunteers assigned female sex at birth (AFAB) or intersex at birth and are of reproductive potential (hereafter referred to as "of pregnancy potential"): negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test at screening (ie, prior to randomization) and prior to study product administration on the day of study product administration. Persons who are NOT of pregnancy potential including having reached menopause (no menses for 1 year) or having undergone hysterectomy or bilateral oophorectomy, or tubal ligation (verified by medical records) are not required to undergo pregnancy testing.
• Reproductive status: A volunteer of pregnancy potential:

You may not qualify if…

• Weight less than 40 kg
• Known significant exposure to TB or receipt of tuberculin skin test in the six months prior enrollment, as determined by the site investigator based on potential participant/parent/guardian report and available medical records. [Note: Significant exposure is defined as close contact with a person who has active TB and has not completed TB treatment. Close contact is defined as sleeping in the same contiguous house/dwelling, and/or working or socializing in close proximity in an enclosed space frequently (eg, several times a week).]
• History of prior active TB disease, as determined by the site investigator based on participant/parent/guardian report and available medical, laboratory or radiographic records.
• Evidence of active TB disease as determined by the site investigator based on participant/parent/guardian report and available medical records, results from physical examination, two-view chest X-ray, and M.tb nucleic acid testing from an expectorated sputum, including a review of any available radiography; and, for volunteers living with HIV and a CD4 count <200 cells/mm3, a positive urine LAM test.
• Receipt of TB preventive therapy within 28 days prior to enrollment or expected to initiate TB preventive therapy during the study as determined by the site investigator based on participant/parent/guardian report and available medical records Note: Clinical indication for receipt of TB preventive therapy will be determined by the site investigator consistent with local standard guidelines. Potential participants on TB preventive therapy during screening may be enrolled once the exclusionary timeframes indicated above have elapsed. If the screening period is exceeded while this requirement is being met, a new screening attempt should be initiated.
• For volunteers living with HIV: current active AIDS-defining condition as determined by the site investigator based on participant/parent/guardian report and available medical records
• Blood products received within 120 days before vaccination.
• Investigational study products (non-vaccine) received within 28 days before vaccination.
• Pregnant or breastfeeding.
• Investigational TB vaccine(s) received in a prior TB vaccine trial or BCG vaccination outside infancy. For volunteers who have received control/placebo in a TB vaccine trial, the HVTN 605/A5421 PSRT will determine eligibility on a case-by-case basis.
• Investigational non-TB vaccine(s) received within the last 1 year in a prior vaccine trial. Exceptions may be made by the HVTN 605/A5421 PSRT for vaccines that have subsequently undergone licensure by the FDA or by the national regulatory authority where the volunteer is enrolling. For volunteers who have received control/placebo in an experimental vaccine trial, the HVTN 605/A5421 PSRT will determine eligibility on a case-by-case basis. For volunteers who have received an experimental vaccine(s) greater than 1 years ago, eligibility for enrollment will be determined by the HVTN 605/A5421 PSRT on a case-by-case basis.
• Live attenuated vaccines received within 28 days before first vaccination or scheduled within 28 days after injection (eg, measles, mumps, and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever; live attenuated influenza vaccine).
• Any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (eg, tetanus, pneumococcal, Hepatitis A or B).
• Allergy treatment with antigen injections within 28 days before first vaccination or that are scheduled within 14 days after first vaccination.
• Immunosuppressive medications received within 168 days before first vaccination (Not exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatologic condition; or [4] a single course of oral/parenteral prednisone or equivalent at doses < 60 mg/day and length of therapy < 11 days with completion at least 30 days prior to enrollment).
• Serious adverse reactions to vaccines or to vaccine components including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from participation: a volunteer who had a non-anaphylactic adverse reaction to pertussis vaccine as a child).
• Immunoglobulin received within 90 days before vaccination.
• Autoimmune disease, current or history (Not exclusionary: mild, well-controlled psoriasis)
• Immunodeficiency (Not exclusionary: HIV).
• Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
• A process that would affect the immune response,
• A process that would require medication that affects the immune response,
• Any contraindication to repeated injections or blood draws,
• A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period,
• A condition or process for which signs or symptoms could be confused with reactions to vaccine, or

Where it is running

• Johannesburg - CHRU — Westdene, Gauteng, South Africa (enrolling)
• Durban - Isipingo — Isipingo, South Africa (enrolling)
• Klerksdorp — Klerksdorp, South Africa (enrolling)
• Ladysmith — Ladysmith, South Africa (enrolling)
• Cape Town - UCTLI — Cape Town, Western Cape, South Africa (enrolling)
• Durban - Botha's Hill CRS — Durban, KwaZulu-Natal, South Africa (enrolling)
• Cape Town - Groote Schuur — Cape Town, Western Cape, South Africa (enrolling)
• Worcester - SATVI — Worcester, Western Cape, South Africa (enrolling)
• Cape Town - Khayelitsha — Cape Town, South Africa (enrolling)
• Durban - Chatsworth — Chatsworth, South Africa (enrolling)
• Soshanguve — Soshanguve, South Africa
• Durban - Wentworth — Durban, KwaZulu-Natal, South Africa
• Cape Town - Emavundleni — Cape Town, Western Cape, South Africa
• Durban eThekwini — Durban, South Africa
• Rustenburg CRS — Rustenburg, South Africa
• Soweto - Gauteng — Johannesburg, Gauteng, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.